No abstract

In December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China. Since the outbreak of the pandemic, in addition to the well-known COVID-19 symptoms, various neurological symptoms have been also described in patients with COVID-19. Here, we report an unusual presentation of COVID-19 infection in a teriflunomide-treated individual with multiple sclerosis (MS) who did not interrupt teriflunomide treatment during the infection. The course of the infection was mild in this case as in other reported teriflunomide-treated individuals with COVID-19. COVID-19’s presentation may be unusual in people with MS (pwMS). It can also be concluded that teriflunomide may be considered a safe disease-modifying treatment option during the pandemic.

Introduction It is not always easy to diagnose pulmonary neuroendocrine tumors (PNET).The aim of the present study is to make a differential diagnosis by studying the same markers in patients with non-small-cell lung carcinoma (NSCLC), patients with benign lung disease (chronic obstructive pulmonary disease and pneumonia) and healthy volunteers to determine the roles of these markers in pulmonary neuroendocrine tumors (PNET) diagnosis and to identify their power. Methods A total of 100 participants including 23 PNET patients and 28 NSCLC patients who were pathologically diagnosed but not yet treated, 25 participants with benign disease and 24 healthy volunteers were included in this cross-sectional study. Results No significant difference was found between the chromogranin A (CgA)and squamous cell carcinoma antigen 1 (SCCA1) values among the groups (PNET - NSCLC - Benign - Healthy volunteers)but the difference in progesterone-releasing peptide (Pro-GRP), neuron-specific enolase (NSE) and adjusted NSE was statistically significant (P values were respectively Pro-GRP p = 0.006, NSE p = 0.015, NSE adjusted p = 0.09).In a comparison of the PNET-NSCLC groups, having a Pro-GRP value higher than 84.6 pg / mL revealed PNET with 60.9% sensitivity and 89.3% specificity (p=0.001). Conclusion The Pro-GRP value is the only indicator that distinguishes the PNET group from the other 3 groups.

No abstract